Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Allard

Showing results (141-150 of 176) with videos related to

Pageof 18
Sort By:
HIV Medicine|April 10, 2023
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in BelgiumRakan Nasreddine, Eric Florence, Jean Cyr Yombi, et al.
HIV Medicine|August 8, 2022
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in BelgiumRakan Nasreddine, Jean Cyr Yombi, Gilles Darcis, et al.
Sexual Health|December 1, 2018
High uptake of pre-exposure prophylaxis (PrEP) during early roll-out in Belgium: results from surveillance reportsBea Vuylsteke, Thijs Reyniers, Catherine Lucet, et al.
Vaccine|June 10, 2008
Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and NefSabine D Allard, Katrien Pletinckx, Karine Breckpot, et al.
HIV Medicine|August 9, 2022
Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapyRonald D'Amico, Santiago Cenoz Gomis, Riya Moodley, et al.
American Journal of Respiratory and Critical Care Medicine|May 29, 2010
Heparin-binding, hemagglutinin-specific IFN-gamma synthesis at the site of infection during active tuberculosis in humansSammy Place, Virginie Verscheure, Nour de San, et al.
Inflammatory Bowel Diseases|September 26, 2019
Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's DiseaseMark T Osterman, Ilyssa O Gordon, Elisabeth M Davis, et al.
Journal of Virus Eradication|October 15, 2024
Staging of immuno-virological dynamics during acute HIV infection in a Belgian prospective cohort studyJozefien De Clercq, Marie-Angélique De Scheerder, Sophie Vanherrewege, et al.
Viruses|October 27, 2022
Healthcare-Associated COVID-19 across Five Pandemic Waves: Prediction Models and Genomic AnalysesThomas Demuyser, Lucie Seyler, Rhea Buttiens, et al.
Journal of the International AIDS Society|February 29, 2020
Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcriptionPieter Pannus, Sofie Rutsaert, Stéphane De Wit, et al.
Pageof 18

Showing results (141-150 of 176) with videos related to

Sort By:
Pageof 18
HIV Medicine|April 10, 2023
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in BelgiumRakan Nasreddine, Eric Florence, Jean Cyr Yombi, et al.
HIV Medicine|August 8, 2022
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in BelgiumRakan Nasreddine, Jean Cyr Yombi, Gilles Darcis, et al.
Sexual Health|December 1, 2018
High uptake of pre-exposure prophylaxis (PrEP) during early roll-out in Belgium: results from surveillance reportsBea Vuylsteke, Thijs Reyniers, Catherine Lucet, et al.
Vaccine|June 10, 2008
Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and NefSabine D Allard, Katrien Pletinckx, Karine Breckpot, et al.
HIV Medicine|August 9, 2022
Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapyRonald D'Amico, Santiago Cenoz Gomis, Riya Moodley, et al.
American Journal of Respiratory and Critical Care Medicine|May 29, 2010
Heparin-binding, hemagglutinin-specific IFN-gamma synthesis at the site of infection during active tuberculosis in humansSammy Place, Virginie Verscheure, Nour de San, et al.
Inflammatory Bowel Diseases|September 26, 2019
Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's DiseaseMark T Osterman, Ilyssa O Gordon, Elisabeth M Davis, et al.
Journal of Virus Eradication|October 15, 2024
Staging of immuno-virological dynamics during acute HIV infection in a Belgian prospective cohort studyJozefien De Clercq, Marie-Angélique De Scheerder, Sophie Vanherrewege, et al.
Viruses|October 27, 2022
Healthcare-Associated COVID-19 across Five Pandemic Waves: Prediction Models and Genomic AnalysesThomas Demuyser, Lucie Seyler, Rhea Buttiens, et al.
Journal of the International AIDS Society|February 29, 2020
Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcriptionPieter Pannus, Sofie Rutsaert, Stéphane De Wit, et al.
Pageof 18